COVID-19住院出院后静脉血栓栓塞症的发生情况
该质量改进项目纳入1877例COVID-19相关出院,出院后42天内诊断医院相关静脉血栓栓塞症(HA-VTE)9例,出院后发生率为4.8/1000例出院;2019年18159例内科出院后42天内HA-VTE 56例(3.1/1000例出院)。COVID-19组与2019年组出院后HA-VTE的比值比为1.6(95%CI 0.77-3.1)。
要点
- COVID-19住院患者出院后42天内HA-VTE发生率为4.8/1000例出院。
- COVID-19住院未见增加出院后HA-VTE风险,出院后血栓预防需随机对照试验评估。
核心结论
- COVID-19住院与因其他急性内科疾病住院相比,似乎不增加出院后HA-VTE的风险。
- 出院后血栓预防的风险获益比仍不确定,需要随机对照试验评估COVID-19患者出院后继续血栓预防的作用。
研究设计与样本
- 本研究报告来自一项持续进行的质量改进项目,该项目纳入医院相关静脉血栓栓塞症(HA-VTE)的根本原因分析。
- 本地方案仅在COVID-19患者住院期间提供血栓预防。
- 分析了1877例COVID-19相关出院后42天内的出院后VTE数据。
- 对照为2019年18159例内科住院相关出院后42天内的HA-VTE数据。
主要发现
- COVID-19相关出院后42天内诊断HA-VTE 9例,出院后发生率为4.8/1000例出院。
- 2019年内科住院相关出院后42天内HA-VTE 56例,发生率为3.1/1000例出院。
- COVID-19组与2019年组出院后HA-VTE的比值比为1.6(95%CI 0.77-3.1)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为需要随机对照试验评估COVID-19患者出院后继续血栓预防的作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The association of severe coronavirus disease 2019 (COVID-19) with an increased risk of venous thromboembolism (VTE) has resulted in specific guidelines for its prevention and management. The VTE risk appears highest in those with critical care admission. The need for postdischarge thromboprophylaxis remains controversial, which is reflected in conflicting expert guideline recommendations. Our local protocol provides thromboprophylaxis to COVID-19 patients during admission only. We report postdischarge VTE data from an ongoing quality improvement program incorporating root-cause analysis of hospital-associated VTE (HA-VTE). Following 1877 hospital discharges associated with COVID-19, 9 episodes of HA-VTE were diagnosed within 42 days, giving a postdischarge rate of 4.8 per 1000 discharges. Over 2019, following 18 159 discharges associated with a medical admission; there were 56 episodes of HA-VTE within 42 days (3.1 per 1000 discharges). The odds ratio for postdischarge HA-VTE associated with COVID-19 compared with 2019 was 1.6 (95% confidence interval, 0.77-3.1). COVID-19 hospitalization does not appear to increase the risk of postdischarge HA-VTE compared with hospitalization with other acute medical illness. Given that the risk-benefit ratio of postdischarge thromboprophylaxis remains uncertain, randomized controlled trials to evaluate the role of continuing thromboprophylaxis in COVID-19 patients following hospital discharge are required.
引用
- Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020. PMID: 32746455. doi:10.1182/blood.2020008086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。